Results from the NOBLE trial presented at TCT 2016 and published in The Lancet

(Cardiovascular Research Foundation) Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic-Baltic-British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news